🔗 Share this article

Given that the US proceeds with historic changes to its immunization guidelines, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by expressing skepticism about coronavirus vaccines in the pandemic and has zeroed in on alleged deaths following Covid immunization in her short tenure at the Food and Drug Administration.

Scheduled Shifts to Pediatric Vaccine Schedule

Health officials planned to announce sweeping revisions to the pediatric immunization program earlier this month, bringing the US with the Danish vaccine program, sources say – a substantial departure that would put the US out of alignment with much of the world with insufficient data for benefit. The announcement has been pushed back until the coming year.

Rather than Vinay Prasad, Høeg is scheduled to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s CDER, the fifth person to head the division this year.

A New Direction at the FDA

This interim role may indicate a strengthened alliance between the drug and biologics centers as Høeg and Dr. Prasad consolidate power at the agency – and it signals a renewed priority upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for ending some pediatric shot schedules in the US in order to be more in line with the Danish model, a society with comprehensive healthcare and a population roughly the population of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on immunizations – typically the responsibility of Dr. Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Qualifications

Høeg has no apparent track record in medication creation, approval processes or leadership, which has been typical for previous leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for leading the CDER, remarked a neurologist and psychiatrist. “She’s never run a scientific study. She has no expertise in managing a major agency. She is not an expert in industry regulation.”

Former commissioners of the center would “understand legal statutes and the science of drug development”, noted a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that former directors who ran CBER have had.”

The drug center has an immense range of responsibilities at the FDA, the former commissioner pointed out.

“Everybody just pays attention on the novel medication approvals, but the generic program clears numerous generic drugs. There’s a biosimilars program, OTC medication office and so forth, and every single one need to be supervised,” Dr. Woodcock explained. “The thing you overlook, that’s the thing that I always told people is going to bite you.”

Furthermore, a major administrative element to the role, which supervises more than 5,000 employees. “It’s a huge administrative position, if you execute it properly,” she concluded.

Response and Contentious Initiatives

Regarding inquiries about Dr. Høeg's credentials and whether this assignment signifies increased cooperation among FDA leaders on immunizations, a press secretary said that the “questions rely on inaccurate premises”.

“This background aligns with the functions of her role,” the spokesperson explained, pointing to the time Dr. Høeg spent guiding the agency head on “drug safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's recently launched priority voucher program, a controversial expedited drug-approval program that apparently worried her former heads. “By what process are these therapies being selected for this voucher program? Who takes the calls?” Dr. Howard asked. “There’s a lot of confidentiality happening at the FDA right now.”

In general, he stated, “the FDA looks to be trending towards less stringent oversight of pharmaceuticals, except for vaccines.”

Documented Track Record on Immunizations

Concerning immunizations, Høeg has a clearer, if troubling, history, critics observe. She authored a research paper using non-validated crowd-sourced reports to determine the frequency of myocarditis following COVID-19 immunization. She counseled the Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Part of her “desired changes” for the incoming federal leadership included changing regulations for novel immunizations and halting “unnecessary” vaccines, she said post-election on a online show. At the FDA, Høeg has reportedly floated the idea of preventing young men from obtaining COVID-19 vaccinations.

“She is an thorough ideologue who starts off with her beliefs and reverse-engineers to fit the data in a very misleading, dishonest way,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Høeg joined other contrarians, {like|